New hope for Hard-to-Treat cancers: experimental PARP inhibitor enters human trials
NCT ID NCT06380660
First seen Jan 08, 2026
Summary
This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or stopping tumor growth. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors in people with cancers like ovarian, breast, or prostate cancer linked to BRCA gene mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anyang Cancer Hospital
RECRUITINGAnyang, Henan, China
-
Chongqing Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, China
-
First Hospital Affiliated to Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, China
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, China
-
Qilu Hospital Shangdong University
RECRUITINGJinan, Shandong, China
-
Second Hospital Affiliated to Shanxi Medical University
RECRUITINGTaiyuan, Shanxi, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.